172 related articles for article (PubMed ID: 1992185)
1. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States.
Fradkin JE; Schonberger LB; Mills JL; Gunn WJ; Piper JM; Wysowski DK; Thomson R; Durako S; Brown P
JAMA; 1991 Feb; 265(7):880-4. PubMed ID: 1992185
[TBL] [Abstract][Full Text] [Related]
2. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977.
Abrams JY; Schonberger LB; Belay ED; Maddox RA; Leschek EW; Mills JL; Wysowski DK; Fradkin JE
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1666-9. PubMed ID: 21816775
[TBL] [Abstract][Full Text] [Related]
3. Creutzfeldt-Jakob disease risk in Slovak recipients of human pituitary growth hormone.
Mitrova E; Belay G
Bratisl Lek Listy; 1999 Apr; 100(4):187-91. PubMed ID: 10914140
[TBL] [Abstract][Full Text] [Related]
4. Human growth hormone and Creutzfeldt-Jakob disease.
Zekauskas S; Boggs MB; Wilson DP
J Okla State Med Assoc; 1990 Sep; 83(9):447-8. PubMed ID: 2280278
[TBL] [Abstract][Full Text] [Related]
5. [Creutzfeldt-Jakob disease in 4 children treated with growth hormone].
Billette de Villemeur T; Gourmelen M; Beauvais P; Rodriguez D; Vaudour G; Deslys JP; Dormont D; Richard P; Richardet JM
Rev Neurol (Paris); 1992; 148(5):328-34. PubMed ID: 1448646
[TBL] [Abstract][Full Text] [Related]
6. Status report on the US human growth hormone recipient follow-up study.
Mills JL; Fradkin J; Schonberger L; Gunn W; Thomson RA; Piper J; Wysowski D; Brown P
Horm Res; 1990; 33(2-4):116-9; discussion 120. PubMed ID: 2210615
[TBL] [Abstract][Full Text] [Related]
7. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.
Huillard d'Aignaux J; Costagliola D; Maccario J; Billette de Villemeur T; Brandel JP; Deslys JP; Hauw JJ; Chaussain JL; Agid Y; Dormont D; Alpérovitch A
Neurology; 1999 Oct; 53(6):1197-201. PubMed ID: 10522872
[TBL] [Abstract][Full Text] [Related]
8. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?
Boyd A; Klug GM; Schonberger LB; McGlade A; Brandel JP; Masters CL; Collins SJ
Med J Aust; 2010 Sep; 193(6):366-9. PubMed ID: 20854243
[TBL] [Abstract][Full Text] [Related]
9. Creutzfeldt-Jakob disease following pituitary-derived human growth hormone therapy: a new American case.
Marzewski DJ; Towfighi J; Harrington MG; Merril CR; Brown P
Neurology; 1988 Jul; 38(7):1131-3. PubMed ID: 3290703
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK.
Ritchie DL; Adlard P; Peden AH; Lowrie S; Le Grice M; Burns K; Jackson RJ; Yull H; Keogh MJ; Wei W; Chinnery PF; Head MW; Ironside JW
Acta Neuropathol; 2017 Aug; 134(2):221-240. PubMed ID: 28349199
[TBL] [Abstract][Full Text] [Related]
11. Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients.
Douet JY; Huor A; Cassard H; Lugan S; Aron N; Mesic C; Vilette D; Barrio T; Streichenberger N; Perret-Liaudet A; Delisle MB; Péran P; Deslys JP; Comoy E; Vilotte JL; Goudarzi K; Béringue V; Barria MA; Ritchie DL; Ironside JW; Andréoletti O
Acta Neuropathol Commun; 2021 Aug; 9(1):145. PubMed ID: 34454616
[TBL] [Abstract][Full Text] [Related]
12. The clinical neurology and epidemiology of Creutzfeldt-Jakob disease, with special reference to iatrogenic cases.
Brown P
Ciba Found Symp; 1988; 135():3-23. PubMed ID: 3044708
[TBL] [Abstract][Full Text] [Related]
13. Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone.
Croes EA; Roks G; Jansen GH; Nijssen PC; van Duijn CM
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):792-3. PubMed ID: 12023427
[TBL] [Abstract][Full Text] [Related]
14. Human pituitary growth hormone (hGH) and Creutzfeldt-Jakob disease: results of an epidemiological survey in France, 1986.
Goujard J; Entat M; Maillard F; Mugnier E; Rappaport R; Job JC
Int J Epidemiol; 1988 Jun; 17(2):423-7. PubMed ID: 3042652
[TBL] [Abstract][Full Text] [Related]
15. Creutzfeldt-Jakob disease after administration of human growth hormone.
Powell-Jackson J; Weller RO; Kennedy P; Preece MA; Whitcombe EM; Newsom-Davis J
Lancet; 1985 Aug; 2(8449):244-6. PubMed ID: 2862420
[TBL] [Abstract][Full Text] [Related]
16. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.
Swerdlow AJ; Higgins CD; Adlard P; Jones ME; Preece MA
Neurology; 2003 Sep; 61(6):783-91. PubMed ID: 14504321
[TBL] [Abstract][Full Text] [Related]
17. Similar genetic susceptibility in iatrogenic and sporadic Creutzfeldt-Jakob disease.
Deslys JP; Marcé D; Dormont D
J Gen Virol; 1994 Jan; 75 ( Pt 1)():23-7. PubMed ID: 8113733
[TBL] [Abstract][Full Text] [Related]
18. A nationwide cohort study on Creutzfeldt-Jakob disease among human growth hormone recipients.
Wientjens DP; Rikken B; Wit JM; Hofman A; Stricker BH
Neuroepidemiology; 2000; 19(4):201-5. PubMed ID: 10859499
[TBL] [Abstract][Full Text] [Related]
19. Human growth hormone therapy and Creutzfeldt-Jakob disease: a drama in three acts.
Brown P
Pediatrics; 1988 Jan; 81(1):85-92. PubMed ID: 3275936
[No Abstract] [Full Text] [Related]
20. Clinical review 58: Creutzfeldt-Jakob disease in recipients of pituitary hormones.
Frasier SD; Foley TP
J Clin Endocrinol Metab; 1994 Jun; 78(6):1277-9. PubMed ID: 8200924
[No Abstract] [Full Text] [Related]
[Next] [New Search]
